Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-30 17:59:11 UTC |
---|
Update Date | 2014-12-24 20:26:08 UTC |
---|
Accession Number | T3D3539 |
---|
Identification |
---|
Common Name | Thalidomide |
---|
Class | Small Molecule |
---|
Description | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] |
---|
Compound Type | - Amide
- Amine
- Angiogenesis Inhibitor
- Drug
- Ester
- Immunosuppressive Agent
- Leprostatic Agent
- Metabolite
- Organic Compound
- Synthetic Compound
- Teratogen
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | (+-)-N-(2,6-dioxo-3-Piperidyl)phthalimide | (+-)-Thalidomide | (±)-N-(2,6-dioxo-3-piperidyl)phthalimide | (±)-thalidomide | 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline | 2,6-dioxo-3-phthalimidopiperidine | 3-Phthalimidoglutarimide | alpha-(N-Phthalimido)glutarimide | alpha-N-Phthalylglutaramide | alpha-Phthalimidoglutarimide | Contergan | Distaval | K-17 | N-(2,6-dioxo-3-piperidyl)phthalimide | N-Phthalimidoglutamic acid imide | N-Phthaloylglutamimide | N-Phthalyl-glutaminsaeure-imid | N-Phthalylglutamic acid imide | Pro-ban M | Sedalis | Softenon | Talidomida | Talimol | Thaled | Thalidomidum | Thalidomine USP26 | Thalomid | α-(N-phthalimido)glutarimide | α-N-phthalylglutaramide | α-phthalimidoglutarimide |
|
---|
Chemical Formula | C13H10N2O4 |
---|
Average Molecular Mass | 258.230 g/mol |
---|
Monoisotopic Mass | 258.064 g/mol |
---|
CAS Registry Number | 50-35-1 |
---|
IUPAC Name | 2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione |
---|
Traditional Name | thalidomide |
---|
SMILES | OC1=NC(=O)C(CC1)N1C(=O)C2=CC=CC=C2C1=O |
---|
InChI Identifier | InChI=1/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17) |
---|
InChI Key | InChIKey=UEJJHQNACJXSKW-UHFFFAOYNA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as phthalimides. These are aromatic heterocyclic compounds containing a 1,3-dioxoisoindoline moiety. They are imide derivatives of phthalic anhydrides. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Isoindoles and derivatives |
---|
Sub Class | Isoindolines |
---|
Direct Parent | Phthalimides |
---|
Alternative Parents | |
---|
Substituents | - Phthalimide
- Alpha-amino acid or derivatives
- Isoindole
- Piperidinedione
- Delta-lactam
- Piperidinone
- Benzenoid
- Piperidine
- Carboxylic acid imide, n-substituted
- Carboxylic acid imide
- Dicarboximide
- Carboxylic acid imide, n-unsubstituted
- Lactam
- Carboxylic acid derivative
- Azacycle
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | Thalidomide is an off-white to white, odorless, crystalline powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 270°C | Boiling Point | Not Available | Solubility | 545 mg/L (at 25°C) | LogP | 0.33 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-05d0-4950000000-f29254c7cc48a749c100 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-000i-1940000000-f6d6997d1eaa7a83ec1b | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-000i-0930000000-e92e8e23d5db87f50f53 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-qTof , Positive | splash10-0019-2900000000-ecfd1b7ec17b857ea977 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-000i-0930000000-e92e8e23d5db87f50f53 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-000i-1940000000-f6d6997d1eaa7a83ec1b | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0019-2900000000-ecfd1b7ec17b857ea977 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 60V, Positive | splash10-0aou-3910000000-91636cf8948ff2a1ec8c | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 75V, Negative | splash10-0aou-4900000000-0354536dffa9acdee12d | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 90V, Negative | splash10-066u-6900000000-ea3e7b4b381e65a7c9a4 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 75V, Positive | splash10-0aou-4900000000-c5062441ebfb6523331b | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 45V, Negative | splash10-0bvl-2970000000-1e251d07e623c9fbe2a2 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 60V, Negative | splash10-0aou-3910000000-19940b0b041ba51e96e0 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Negative | splash10-0a6r-0190000000-a818a5ae6100d0f996ba | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 15V, Negative | splash10-0a4i-0090000000-42e8be928c8508c213f2 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 45V, Positive | splash10-0bvl-2970000000-fcf57e68d7f7156f09d4 | 2021-09-20 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0a4i-0090000000-094c39302b7589d69293 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0a4r-0590000000-a8eb9abb005e68bb1fdf | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-000f-9800000000-e219527727ba0e4f62dd | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0a4i-0190000000-88a6f8cb2bfe0f1b603f | 2016-08-04 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0bti-1790000000-bdf020cb11e65e0077f7 | 2016-08-04 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-01oy-9700000000-ce19845489ffe3fdb389 | 2016-08-04 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0bta-0960000000-38a7ecf36472375bfe14 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0a4j-1590000000-40230dba1a083dee9f10 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0005-4900000000-b49c37804603e0525f05 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-052b-0960000000-d36ac6ec3b1b89dff27d | 2021-10-12 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0wba-4900000000-77362eaf27267f59650d | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract. |
---|
Mechanism of Toxicity | In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. |
---|
Metabolism | At the present time, the exact metabolic route and fate of thalidomide is not known in humans. Thalidomide itself does not appear to be hepatically metabolized to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple metabolites. Thalidomide may be metabolized hepatically by enzymes of the cytochrome P450 enzyme system. The end product of metabolism, phthalic acid, is excreted as a glycine conjugate. In a repeat dose study in which THALOMID™ (thalidomide) 200 mg was administered to 10 healthy females for 18 days, thalidomide displayed similar pharmacokinetic profiles on the first and last day of dosing. This suggests that thalidomide does not induce or inhibit its own metabolism.
Route of Elimination: Thalidomide itself has less than 0.7% of the dose excreted in the urine as unchanged drug.
Half Life: The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing. |
---|
Toxicity Values | The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively. |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Used to treat multiple myeloma. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | The most serious toxicity associated with thalidomide is its documented human teratogenicity. The risk of severe birth defects, primarily phocomelia or death to the fetus, is extremely high during the critical period of pregnancy. The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period. The risk of other potentially severe birth defects outside this critical period is unknown, but may be significant. Based on present knowledge, thalidomide must not be used at any time during pregnancy. Thalidomide can cause severe birth defects in humans. |
---|
Symptoms | Thalidomide is associated with drowsiness/somnolence, peripheral neuropathy, dizziness/orthostatic hypotension, neutro-penia, and HIV viral load increase. |
---|
Treatment | Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored. (2) |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01041 |
---|
HMDB ID | HMDB15175 |
---|
PubChem Compound ID | 5426 |
---|
ChEMBL ID | CHEMBL468 |
---|
ChemSpider ID | 5233 |
---|
KEGG ID | C07910 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 9513 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Thalidomide |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Thalidomide |
---|
References |
---|
Synthesis Reference | Jamshed Shah, “Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs.” U.S. Patent US20030139451, issued July 24, 2003. |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- RxList: The Internet Drug Index (2009). [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|
Down-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|